Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRTX NYSEAMERICAN:HEB NASDAQ:HYPD NYSE:IBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRTXBiorestorative Therapies$1.57-1.3%$1.68$1.21▼$2.55$11.93M75.28145,123 shs84,308 shsHEBHemispherx BioPharma$6.70-20.0%$3.58$1.69▼$14.81$16.36MN/A102,599 shs7,639 shsHYPDHyperion DeFi$12.88-18.8%$6.63$0.85▼$124.80$45.72M2.474.81 million shs1.05 million shsIBIOiBio$0.73+0.1%$0.81$0.64▼$6.89$12.08M0.94876,119 shs680,372 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRTXBiorestorative Therapies-1.26%-3.09%-7.65%-10.29%-6.55%HEBHemispherx BioPharma0.00%0.00%0.00%+6,960.06%+1,710.81%HYPDHyperion DeFi-18.79%-2.65%+166.67%+1,092.59%-86.91%IBIOiBio+0.14%-10.26%-18.78%-17.87%-66.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBRTXBiorestorative Therapies3.6011 of 5 stars3.55.00.00.02.13.30.6HEBHemispherx BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AHYPDHyperion DeFi0.9374 of 5 stars1.05.00.00.02.90.00.6IBIOiBio1.2945 of 5 stars3.50.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRTXBiorestorative Therapies 3.00Buy$18.001,046.50% UpsideHEBHemispherx BioPharma 0.00N/AN/AN/AHYPDHyperion DeFi 2.00Hold$2.00-84.47% DownsideIBIOiBio 3.00Buy$4.30488.24% UpsideCurrent Analyst Ratings BreakdownLatest HEB, HYPD, IBIO, and BRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.005/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRTXBiorestorative Therapies$400K29.44N/AN/A$1.23 per share1.28HEBHemispherx BioPharmaN/AN/AN/AN/AN/AN/AHYPDHyperion DeFi$60K618.24N/AN/A($695.52) per share-0.02IBIOiBio$375K32.20N/AN/A$1.41 per share0.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRTXBiorestorative Therapies-$8.98M-$1.47N/AN/AN/A-3,093.61%-129.47%-86.02%8/12/2025 (Estimated)HEBHemispherx BioPharmaN/AN/A0.00∞N/AN/AN/AN/AN/AHYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)IBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/ALatest HEB, HYPD, IBIO, and BRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BRTXBiorestorative Therapies-$0.41N/AN/AN/A$0.34 millionN/A5/19/2025Q1 2025HYPDHyperion DeFi-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/14/2025Q1 2025BRTXBiorestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRTXBiorestorative TherapiesN/AN/AN/AN/AN/AHEBHemispherx BioPharmaN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRTXBiorestorative TherapiesN/A2.242.24HEBHemispherx BioPharmaN/AN/AN/AHYPDHyperion DeFiN/A0.340.34IBIOiBio0.051.761.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRTXBiorestorative Therapies69.38%HEBHemispherx BioPharmaN/AHYPDHyperion DeFi25.84%IBIOiBio7.90%Insider OwnershipCompanyInsider OwnershipBRTXBiorestorative Therapies25.50%HEBHemispherx BioPharmaN/AHYPDHyperion DeFi7.10%IBIOiBio0.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRTXBiorestorative Therapies77.50 million5.59 millionNot OptionableHEBHemispherx BioPharma312.44 millionN/ANot OptionableHYPDHyperion DeFi402.88 million2.68 millionOptionableIBIOiBio10016.52 million9.82 millionN/AHEB, HYPD, IBIO, and BRTX HeadlinesRecent News About These CompaniesComparing iBio (NYSE:IBIO) & AngioSoma (OTCMKTS:SOAN)July 16 at 2:21 AM | americanbankingnews.comPharos IBio Co Ltd Share Price - Investing.com UKJune 30, 2025 | uk.investing.comiBio Announces Conference Call to Review Myostatin and Activin E Antibody Data and Reveal Third Target in AstralBio Collaboration on June 24 | NasdaqJune 24, 2025 | nasdaq.comiBio Advances Obesity Care with Antibody TherapiesJune 24, 2025 | tipranks.comiBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo ResultsJune 24, 2025 | globenewswire.comiBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference CallJune 23, 2025 | globenewswire.comiBio Extends Promissory Note Maturity to 2026June 18, 2025 | tipranks.comIbio nominates IBIO-610 as obesity development candidateJune 18, 2025 | bioworld.comBiBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 TreatmentJune 16, 2025 | globenewswire.comMinister hails ‘exciting’ degree where students spend two years working in industryMay 29, 2025 | irishtimes.comiBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical ModelMay 5, 2025 | finance.yahoo.comiBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical ModelMay 5, 2025 | globenewswire.comiBio, Inc. Reports Strong Q3 2025 ProgressMay 4, 2025 | tipranks.comiBio Reports Fiscal Third Quarter 2025 Financial ResultsMay 2, 2025 | globenewswire.comiBio, Inc.: iBio Raises $6.2 Million Through Warrant Inducement TransactionApril 30, 2025 | finanznachrichten.deiBio, Inc. Announces Agreement to Exercise Existing Warrants for $6.2 Million in Gross ProceedsApril 29, 2025 | quiverquant.comQiBio Raises $6.2 Million Through Warrant Inducement TransactionApril 29, 2025 | globenewswire.comiBio Enters Licensing Agreement for Obesity TreatmentApril 22, 2025 | tipranks.comiBio, Inc. Enters Licensing Agreement with AstralBio for First-in-Class Activin E-Targeting Antibody to Address Obesity and Cardiometabolic DiseasesApril 22, 2025 | quiverquant.comQiBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBioApril 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHEB, HYPD, IBIO, and BRTX Company DescriptionsBiorestorative Therapies NASDAQ:BRTX$1.57 -0.02 (-1.26%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.60 +0.03 (+1.91%) As of 07/18/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Hemispherx BioPharma NYSEAMERICAN:HEB$6.70 -1.68 (-20.05%) As of 06/13/2025Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.Hyperion DeFi NASDAQ:HYPD$12.88 -2.98 (-18.79%) As of 07/18/2025 04:00 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.iBio NYSE:IBIO$0.73 +0.00 (+0.14%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.73 0.00 (-0.14%) As of 07/18/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
